Sugi Predict

Sugi Predict / Compounds / SCHEMBL2726097

SCHEMBL2726097

SCHEMBL2726097

O=[N+]([O-])c1ccc(N2CCSCC2)cn1

nearest known ligand 0.72

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.72
▸ POLB P06746 1/20 0.68
▸ ALDH1A1 P00352 2/20 0.59
▸ RAB9A P51151 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ CHRNB2 P17787 3/20 0.53
▸ CHRNA4 P43681 3/20 0.53
▸ CHRNB4 P30926 2/20 0.53
▸ CHRNA3 P32297 2/20 0.53
▸ THRB P10828 1/20 0.51
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ LGMN Q99538 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2722928 0.87 MAPT (0.59) MAPTPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL29435521 0.85 MAPT (0.97) MAPTPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL15141576 0.85 MAPT (0.97) MAPTPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL3539759 0.85 MAPT (0.90) MAPTPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL2722856 0.84 MAPT (1.00) MAPTPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL29437410 0.84 MAPT (1.00) MAPTPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL31073302 0.83 MAPT (0.74) MAPTPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL20676972 0.83 MAPT (0.74) MAPTPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL1392957 0.81 MAPT (0.72) MAPTPOLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL521907 0.81 MAPT (0.72) MAPTPOLBALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4596051-A2 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION Pharmacosmos Holding A/s (DK) 2025-08-06 — — EP disclosed
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors PHARMACOSMOS HOLDING A/S (DK) 2025-04-29 — — US disclosed
EP-2968291-B1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION PHARMACOSMOS HOLDING AS (DK) 2025-04-16 — — EP disclosed
US-20240109906-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2024-04-04 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237533-A1 CDK Inhibitors G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
EP-2632467-A1 CDK INHIBITORS G1 Therapeutics, Inc. (US) 2013-09-04 — — EP disclosed
WO-2012061156-A1 CDK INHIBITORS TAVARES FRANCIS X (US) 2012-05-10 — — WO disclosed
WO-2012061156-A1 CDK INHIBITORS TAVARES FRANCIS X (US) 2012-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237534-A1 CDK INHIBITORS CDK3, CDK9, CDK6 MAPT 2057/4885POLB 252/4885ALDH1A1 2981/4885
US-20240109906-A1 CDK INHIBITORS CDK3, CDK9, CDK6 MAPT 2057/4885POLB 252/4885ALDH1A1 2981/4885
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION RB1, CDK4, CDKN1A MAPT 2961/4885POLB 1353/4885ALDH1A1 1183/4885
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors RB1, CDK4, CDK6 MAPT 3872/4885POLB 139/4885ALDH1A1 3059/4885
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY CDK6, CCNC, MCL1 MAPT 4062/4885POLB 224/4885ALDH1A1 1726/4885
US-20130237533-A1 CDK Inhibitors CDK3, CDK9, CDK6 MAPT 2057/4885POLB 252/4885ALDH1A1 2981/4885
US-20130237544-A1 CDK INHIBITORS CDK3, CDK9, CDK6 MAPT 2057/4885POLB 252/4885ALDH1A1 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.